The company announced the results after market hours on Thursday, 26 April 2012.
Meanwhile, the BSE Sensex was up 74.84 points or 0.44% to 17,205.51.
On BSE, 14,000 shares were traded in the counter as against average daily volume of 18,247 shares in the past one quarter.
The stock hit a high of Rs 560.20 and a low of Rs 548 so far during the day. The stock had hit a record high of Rs 571 on 25 April 2012. The stock had hit a 52-week low of Rs 237.10 on 27 April 2011.
The small-cap stock had outperformed the market over the past one month till 26 April 2012, rising 19.08% compared with the Sensex's 0.46% gain. The scrip had also outperformed the market in past one quarter, surging 56.02% as against Sensex's 0.31% gain.
The company has an equity capital of Rs 11.71 crore. Face value per share is Rs 10.
Ajanta Pharma's net profit rose 43.1% to Rs 66.49 crore on 31% growth in net sales to Rs 598.25 crore in the year ended 31 March 2012 over the year ended 31 March 2011. Consolidated net profit jumped 52.4% to Rs 77.27 crore on 35% growth in net sales to Rs 671.38 crore in the year ended 31 March 2012 over the year ended 31 March 2011.
Ajanta Pharma said it continues to aggressively execute the strategy of specialty player in the branded generic market in India and Rest of the World (ROW). In the regulated market, the company continues to build its abbreviated new drug application (ANDA) portfolio in the US. During Q4 March 2012, the company filed another 2 ANDAs in the US, taking the total ANDAs under review with the Food and Drug Administration (FDA) to 7. For the 2 ANDAs for which company received approval, sales shall start from Q1 June 2012, the company said.
Ajanta Pharma's board of directors at a meeting held on Thursday, 26 April 2012, recommended dividend of Rs 7.50 per share for the year ended March 2012. Further, the board also approved a 2-for-1 stock split.
Ajanta Pharma is a speciality pharmaceutical formulation company, having leading brands in the therapeutic segments of Ophthalmology, Dermatology and Cardiology. The company exports its products to more than 25 countries.